20:51 EDT Cathie Wood’s ARK Investment buys 262K shares of Crispr Therapeutics (CRSP) today
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG: Promising Partnership with Sirius Therapeutics Amidst Clinical and Market Uncertainties Warrants Hold Rating
- Crispr Therapeutics call volume above normal and directionally bullish
- Strategic Growth and De-risking: Gil Blum’s Buy Rating on Crispr Therapeutics AG
- Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline
- Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating